Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Global Active Pharmaceutical Ingredients (API) and Pharmaceutical Excipients Market Research Report 2022-2029 – Increasing Scope of HPAPI and Advanced Next Generation Biologics Market

Published

on

<!– Name:DistributionId Value:8782271 –> <!– Name:EnableQuoteCarouselOnPnr Value:False –> <!– Name:IcbCode Value:2790 –> <!– Name:CustomerId Value:1026737 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:671ebbfb-03eb-4d8e-97bf-c14b593ce0b7 –>

Dublin, March 06, 2023 (GLOBE NEWSWIRE) — The “Active Pharmaceutical Ingredients (API) Global Market – Forecast To 2029” & “Pharmaceutical Excipients Global Market – Forecast To 2029” report has been added to ResearchAndMarkets.com’s offering.

Generally, each drug made up of two components that are API and excipients, having curative activity. APIs are often known as bulk pharmaceuticals and most of all APIs are in powder form. Active Pharmaceutical Ingredients (APIs) are active substances in a drug intended to achieve pharmacological activity which is having a direct effect on disease treatment. APIs are synthesized based on chemical synthesis, fermentation, biotechnological methods or enhanced from the natural source.

North America accounted for the highest revenue in 2022 and is expected to grow at a mid single digit CAGR from 2022 to 2029. Growing pharma R&D expenditure, increasing development of new drugs over the time, increasing approval of generics and biosimilars, growing biopharmaceutical drugs pipelines, presence of number of API manufacturing facilities for all regulated drug products, increasing scope of highly potent drugs, government support to expand the domestic pharmaceutical manufacturing facilities and increase in the prevalence of infectious diseases, cancer, central nervous system associated diseases, cardiac disease, and musculoskeletal disorder are some of the major diseases that are driving the market growth. Asia-Pacific is the fastest-growing region with a high single digit CAGR from 2022 to 2029.

The factors such as increasing generic pharmaceuticals and vaccines production, number of pharma companies with a strong network of manufacturing facilities, increasing outsourcing with number of CMO’s and expanding manufacturing facilities, increasing development of new pharma and biopharma drugs, growing biotech R&D investment, presence of number of innovative biotech startups, presence of dedicated departments to support biotechnology research, increasing government investment to support the pharma and biotech industry, low labor cost, and increased prevalence of infectious and other chronic diseases are driving the market growth.

Some of the key players of Active pharmaceutical Ingredient (API) market are

  • Catalent Inc.
  • Divis Laboratories
  • Euroapi
  • Lonza Group Ltd.
  • Pfizer Inc.
  • Samsung Biologics Co. Ltd.
  • Teva Pharmaceutical Industries Limited.
  • Thermo Fisher Scientific Inc
  • Wuxi Apptec Co. Ltd.
  • Wuxi Biologics (Cayman) Inc.

Key Topics Covered:

1 Executive Summary

2 Introduction
2.1 Key Takeaways
2.2 Scope of the Report
2.3 Report Description
2.4 Markets Covered
2.5 Stakeholders
2.6 Research Methodology

3 Market Analysis
3.1 Introduction
3.2 Market Segmentation
3.3 Factors Influencing Market
3.3.1 Drivers and Opportunities
3.3.1.1 Increasing Incidence and Prevalence of Chronic, Communicable and Autoimmune Diseases
3.3.1.2 Adoption of Biologics in Disease Management and Increasing Regulatory Approvals
3.3.1.3 Increasing Investment in Research and Development (R&D) and Expansion of Manufacturing Facilities
3.3.1.4 Patent Expiration of Major Drugs
3.3.1.5 Increasing Scope of Hpapi and Advanced Next Generation Biologics Market
3.3.1.6 Increasing Trend of Outsourcing and Adoption in Emerging Market
3.3.1.7 Increase in the Geriatric Population
3.3.2 Restraints and Threats
3.3.2.1 Contamination of API
3.3.2.2 High Cost for Manufacturing Apis
3.3.2.3 a Requirement of Highly Skilled Technicians
3.3.2.4 Pierce Competition Between API Players
3.3.2.5 Presence of Alternatives
3.3.2.6 Stringent Regulatory Policies and Environmental Concerns
3.4 Regulatory Affairs
3.5 Technological Advancements
3.5.1 Introduction
3.5.2 Automation and Control
3.5.3 Continuous Flow Manufacturing
3.5.4 Cryogenic Technology
3.5.5 Single – Use System (Sus)
3.5.6 Artificial Intelligence in API Manufacturing
3.5.7 Chemistry in Water
3.5.8 M-Rna Technology in Vaccine Manufacturing
3.5.9 Advancements in Hpapi Manufacturing
3.6 Porter’s Five Force Analysis
3.7 Supply Chain Analysis
3.8 Market Share Analysis
3.9 Fda Approved API Manufacturing Units
3.10 Pharmaceutical API Production Volume
3.11 Patent Expiry and Anda Approvals
3.12 Drug Master Filing (Dmf)
3.13 Repurposed Drugs for COVID-19 Treatment
3.14 Acquisition, Merger, and Expansions in API Manufacturing
3.15 Selected Top Selling API
3.16 API Manufacturers Revenue and Capabilities Table

4 API Global Market, Based on Synthesis
4.1 Introduction
4.2 Synthetic API
4.2.1 Synthetic API Based on Customer Base
4.3 Biotech API
4.3.1 Antibodies
4.3.2 Recombinant Proteins
4.3.3 Vaccines
4.3.4 Gene Therapy
4.3.5 Cell Therapy
4.3.6 Other Biotech API
4.3.7 Biotech API Based on Customer Base
4.3.7.1 Biologic API
4.3.7.2 Biosimilar API
4.4 Hpapi
4.4.1 Hpapi Based on Customer Base

5 API Global Market, Based on Business Type
5.1 Introduction
5.2 Captive API Based on Type
5.2.1 Branded Captive API
5.2.2 Generic Captive API
5.3 Merchant API Based on Type
5.3.1 Branded Merchant API
5.3.2 Generic Merchant API

6 API Global Market, Based on Application
6.1 Introduction
6.2 Infectious Diseases
6.3 Oncology
6.4 Cardiovascular Diseases
6.5 Central Nervous System
6.6 Pulmonary Diseases
6.7 Gastrointestinal Diseases
6.8 Endocrine Diseases
6.9 Metabolic Disorders
6.10 Genitourinary Diseases
6.11 Musculoskeletal Diseases
6.12 Other Applications (Nephrology, Hepatology, Opthalmology, Dental, Pain Management, Dermatology,Ent Etc.,)

7 Regional Analysis
7.1 Introduction
7.2 North America
7.2.1 U.S.
7.2.2 Rest of North America
7.3 Europe
7.3.1 Italy
7.3.2 Germany
7.3.3 France
7.3.4 Rest of Europe
7.4 APAC
7.4.1 China
7.4.2 Japan
7.4.3 India
7.4.4 Rest of APAC
7.5 RoW
7.5.1 Brazil
7.5.2 Rest of Latam
7.5.3 Middle East & Others

8 Competitive Landscape
8.1 Introduction
8.2 Collaboration, Partnership and Agreement
8.3 Expansion
8.4 Approvals
8.5 New Product, Service and Technology Launch
8.6 Acquisition
8.7 Others

9 Major Companies
9.1 Overview
9.2 Financials
9.3 Service Portfolio
9.4 Key Developments
9.5 Business Strategy
9.6 SWOT Analysis

Companies Mentioned

  • Aarti Drugs Ltd
  • AbbVie Inc.
  • ACIC Pharmaceuticals Inc.
  • Adimmune Corporation
  • Ajinomoto Bio-Pharma Services
  • Albemarle Corporation
  • Alembic Ltd
  • Alkem laboratories Ltd.
  • Almac Group
  • Alven Laboratories S.r.o.
  • Ambio Pharma Inc.
  • Amneal Pharmaceuticals Inc.
  • Apicore LLC
  • Aragen Life Sciences (GVK Biosciences Private Limited)
  • Arene Lifesciences Limited.
  • AstraZeneca plc
  • Aurobindo Pharma
  • Ampac fine chemicals LLC
  • Axplora
  • BASF SE
  • Bayer AG
  • Bachem holding AG
  • Bal Pharma Ltd.
  • Biocon Limited
  • Biogen Inc.
  • Biomarin Pharmaceutical Inc
  • Biophore India Pharmaceuticals Pvt. Ltd.
  • Biosortia Pharmaceuticals Inc.
  • Biotechnica Pharma Global
  • Blanver
  • Boehringer Ingelheim GmbH
  • Brawn Biotech Ltd.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Limited
  • Curia
  • Catalent, Inc.
  • Cayman Chemicals
  • Celltrion Inc.,
  • Cambrex Corporation
  • Century Pharmaceuticals Ltd
  • CFM Group (AMSA S.P.A)
  • Changzhou Pharmaceutical Factory
  • ChemCon GmbH
  • China Chemical & Pharmaceutical Co., Ltd.
  • Chongqing Huapont Pharmaceutical CO LTD,
  • Cipla Limited
  • CKD Bio
  • Corden Pharma International (Germany)
  • CSL Ltd
  • Daiichi Sankyo Chemical Pharma Co Ltd
  • Daito Pharmaceutical Co., Ltd
  • Dishman Carbogen Amcis
  • Dr.Reddy’s Laboratories
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Emcure Pharmaceuticals Ltd.
  • Ercros S.A.
  • Estechpharma Co., Ltd.
  • Esteve Quimica SA
  • Everest Organics Limited
  • Evonik Industries AG
  • F. Hoffmann-La Roche AG
  • Fareva Group
  • FIS Fabbrica Italiana Sintetici SPA
  • Flamma S.p.A
  • Formosa Laboratories, Inc.
  • Fuji Chemical Industry Co.,Ltd
  • Gentec Pharmaceutical Group S.A (DUKE CHEM and PHARMANOID)
  • Gilead Sciences, Inc.
  • Givaudan (Indena)
  • Gland Pharma Limited
  • GlaxoSmithKline plc
  • Glenmark Pharmaceutical Ltd.
  • GRANULES INDIA LTD.
  • Grupo Ferrer Internacional S.A (Interquim, S.A)
  • Harman Finochem Limited.
  • Heraeus Holding GmbH
  • Hetero Labs Ltd.
  • Hikma pharmaceuticals
  • Hybio Pharmaceutical Co., Ltd.
  • Hikal Ltd.
  • Ibio Inc
  • Inabata Co. Ltd.
  • INTAS PHARMACEUTICALS LTD,
  • Jeil Pharmaceutical Co. Ltd.,
  • Johnson and Johnson
  • Johnson Matthey Pharma Services Inc.
  • Jubilant lifesciences (Jubilant generics Ltd)
  • Katsura Chemical Co.,Ltd.
  • Kern Pharma, S.L.,
  • Kleos pharma
  • Kocak Farma Pharmaceutical
  • Kosher Pharmaceuticals
  • Krka, tovarna zdravil, d. d., Novo mesto
  • Kyowa Hakko Kirin
  • Laboratorium ofichem bv
  • Lannett Company Inc.
  • Laurus Labs
  • Lebsa
  • Lonza group
  • Lusochimica S.p.A
  • LOTUS Pharmaceutical Co., Ltd.
  • Lesaffre (Gnosis S.p.A.)
  • Magle Chemoswed AB
  • Mallinckrodt Pharmaceuticals
  • Medichem S.A
  • Megafine Pharma Ltd
  • Mehta API
  • Merck KGaA
  • Metrochem API
  • Micro Labs LTD
  • Minakem High Potent S.A.
  • Moehs Iberica SL
  • Molcan
  • Morepen
  • MSN Organics Pvt, Ltd.
  • Natco Pharma
  • Neuland laboratories Ltd.
  • Novartis International AG
  • Novo Holdings A/S
  • Olainfarm JSC
  • OLON S.P.A.
  • Orchid Chemicals & Pharmaceuticals Ltd
  • Orion (Fermion)
  • Optimus Drugs Private LTD.
  • Paratek Pharmaceuticals, Inc.
  • Perrigo Company plc,
  • Pfizer Inc.
  • Phyton Biotech LLC
  • Pierre Fabre
  • Polpharma
  • Prajna Generics Pvt. Ltd.
  • Protex International (ICROM S.p.A.)
  • Rablon Healthcare Pvt Ltd
  • Saneca Pharmaceuticals a.s.
  • Sanofi S.A.
  • Solara Active Pharma
  • Seikagaku Corporation
  • SEQUENS (Wavelength Pharmaceuticals)
  • Shiono Chemical Co., Ltd.
  • SM BIOMED SDN. BHD
  • Siegfried Holding AG
  • Standard Chemical & Pharmaceutical Co.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Sun Pharmaceutical Industries Ltd
  • Syn-tech chem. And Pharma.Co., Ltd
  • Takeda Pharmaceutical Company Limited
  • Temad Co.
  • Teva Pharmaceutical industries Ltd.
  • Umicore
  • Unichem Laboratories LTD.
  • Union Quimico Farmaceutica, S.A. UQUIFA,
  • Venus Remedies Limited
  • Vertex Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/r/twt43d

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.


GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

IG Canada Announces Enhanced Trading Platform for Enhanced User Experience

Published

on

ig-canada-announces-enhanced-trading-platform-for-enhanced-user-experience

Meta description : Explore IG Canada’s advanced trading platform, educational resources, and robust security features. Achieve your trading goals with the innovative tools.
NOTTINGHAM, England, April 25, 2024 /PRNewswire/ — IG Canada, a premier online trading platform, is pleased to announce significant enhancements to its trading technology, designed to empower both novice and experienced traders with superior tools and resources. This development is part of IG Canada’s commitment to providing the best trading experience in the Canadian market.

IG Canada has upgraded its platform with advanced features that streamline trading processes and improve the accuracy of trade execution. These enhancements include customizable charts, a wider range of indicators, and improved mobile access, ensuring traders can operate efficiently from anywhere at any time.
Recognizing the importance of education in trading success, IG Canada has expanded its educational resources. The brokerage now offers a comprehensive learning center featuring webinars, tutorials, and articles that cater to various skill levels. These resources are designed to help traders develop robust trading strategies and improve their market knowledge.
Security remains a top priority for IG Canada. The latest updates include enhanced encryption and multi-factor authentication to protect client data and funds. These security measures provide peace of mind for traders, knowing their investments are safeguarded against potential threats.
IG Canada is a leading online brokerage that provides trading services across multiple asset classes, including forex, stocks, commodities, and indices. With a focus on innovation and customer service, IG Canada is committed to helping Canadian traders achieve their investment goals through a transparent and efficient trading environment.
In addition, IG Canada is committed to engaging with the community through upcoming webinars, live events, and partnerships with local financial experts. These initiatives are designed not only to support the growth and education of the clients but also to foster a stronger, more connected trading community in Canada.
Press Contact:Contact Name: Timothy C. SherwinEmail: [email protected] Phone: +447 441425053

View original content:https://www.prnewswire.co.uk/news-releases/ig-canada-announces-enhanced-trading-platform-for-enhanced-user-experience-302127189.html

Continue Reading

Artificial Intelligence

Sentrycs Now Part of the UK National Protective Security Authority Catalog of Security Equipment

Published

on

sentrycs-now-part-of-the-uk-national-protective-security-authority-catalog-of-security-equipment

This inclusion into the NPSA CSE marks a significant milestone in the company’s commitment to enhancing national and international airspace security and to leading the C-UAS market toward multi-layer strategy optimization and excellence.
TEL-AVIV, Israel, April 25, 2024 /PRNewswire/ — Sentrycs, a leading innovator in adaptive counter-drone solutions, is proud to announce its inclusion in the prestigious UK National Protective Security Authority Catalogue of Security Equipment (NPSA CSE).
 
Following a rigorous assessment process, Sentrycs’ cutting-edge Counter Unmanned Aerial Systems (C-UAS) solution has met the high standards set by the NPSA for Detection, Tracking, and Identification (DTI). The testing, conducted at the NPSA’s designated testing facilities in August 2023, rigorously evaluated the Sentrycs system against the NPSA’s DTI Testing and Evaluation Standard v3.1.
Sentrycs elected to be assessed under Configuration D as a 3D system with Ground Control Station (GCS) detection capability and platform identification capability, which is the most demanding test scenario with the highest number of scored parameters.
The Sentrycs system demonstrated exceptional capabilities in various security scenarios, showcasing its robustness in detecting and tracking with high accuracy and zero false alarms. The system’s innovative use of cyber techniques to extract data from targets and its streamlined human-machine interface were especially noted for their efficiency and ease of use.
“Our team is proud to have Sentrycs recognized by the UK National Protective Security Authority,” said Yoav Zaltzman, CEO of Sentrycs. “Being listed in the CSE is not just an honor; it’s a testament to our technology’s reliability and effectiveness in contributing to the ever-changing airspace security landscape.”
Sentrycs’ technology is now accessible through the NPSA CSE, providing security practitioners with verified solutions that meet the UK’s rigorous security standards. This inclusion not only underscores Sentrycs’ role in advancing security technology but also enhances its visibility and credibility on a global stage.
For more details on Sentrycs’ solutions and their impact, visit www.sentrycs.com.
For further information regarding the NPSA and the Catalog of Security Equipment, please visit the NPSA’s official website.
About Sentrycs
Sentrycs is a leader in adaptive counter-drone solutions, supported by innovative technology designed to passively identify, mitigate, and where necessary, intercept unauthorized drones custom-built for various environments – including airports, borders, prisons, critical infrastructure, and mass events. Founded in 2017, Sentrycs’ has offices in Israel and the US, serving customers worldwide. By uniting its field-proven technology and expertise in global drone environments, Sentrycs is leading the way towards a safer and more secure drone-driven future. Learn more at www.sentrycs.com
Video – https://www.youtube.com/watch?v=YBuhpTq5QuM

View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/sentrycs-now-part-of-the-uk-national-protective-security-authority-catalog-of-security-equipment-302126952.html

Continue Reading

Artificial Intelligence

Homestyler to Recruit First Batch of Global Partners in 20 Countries

Published

on

homestyler-to-recruit-first-batch-of-global-partners-in-20-countries

MILAN, April 25, 2024 /PRNewswire/ — Homestyler, a leading all-in-one 3D Design platform and creative community for global designers invested by Easyhome New Retail Group and Alibaba Group, successfully hosted the Homestyler Global Partners Conference and Gorgeous Home Imported Brand Investment Promotion Conference from April 18 to 19 on the sidelines of the 2024 Salone del Mobile Milano, the world’s leading furniture fair.

Easyhome is at the forefront, driving the transformation of the home furnishing industry into a full-service platform. It has developed a tailored solution for global brands called Gorgeous Home, which includes supportive policies and has established local distribution and service networks in international markets. During the conference, Homestyler unveiled a suite of digital products enhanced by 3D and AI technologies, including cloud-based design tools, virtual livestreaming that can alter and restore furnishing scenes to true-to-life scale, a 3D Floor Planner, a 3D Virtual Studio, and a 3D Interactive Panorama, among others. The event also marked the signing ceremony with the first group of global partners.
The Global Partners Program is a key milestone of Homestyler’s roadmap towards global commercialization. It has established close partnerships with around 1,000 global home furnishing companies and design institutions to provide solutions for digital transformation. The first global partners from more than 20 countries and regions will collaborate to explore content creation and marketing potential to deliver effective growth.
In addition, Homestyler shared the unique advantages of its software and cloud designing tools, particularly in cloud rendering, free modeling capabilities, 3D model and material libraries, one-stop workflow, and user-friendliness.
“The core technologies and products of Homestyler extend through all links both online and offline and deeply converge physical experience with digital technologies, such as attracting customers, content design and creation, interactive scene, check-out tracking and more, and we continue to optimize and enhance the 3D scenario shopping experience to empower the transformation and upgrading of the global home furnishing industry,” said Ma Xingjian, head of Homestyler’s overseas business.
Looking ahead, Easyhome and Homestyler aims to establish an international service, regional distribution and dealership system, serving as a bridge between global designers and home furnishing companies worldwide to enable designers residing in different countries and regions to highlight their 3D design solutions and boost shopping experience for the consumers.
As a creative hub for global designers, Homestyler continually expands its model library with home furnishing products from around the world and provides the latest in 3D and AI technologies to help companies promote their products across various channels. Companies such as P Life Concept London, Lahoma Ltd., and Tecnobit S.r.l. are leveraging Homestyler products to enhance the online shopping experience and increase efficiency on their websites. Homestyler plans to introduce more B2B digital products and services, including advanced 3D tools for designing, modeling, rendering, virtual studio shooting, and livestreaming. “Homestyler will further advance our international development: we are planning to establish industry-academy cooperation with Italy’s top design institution, the Polytechnic University of Milan, and the relationship with ADI. With the launch of Global Partners Program, Homestyler will continue to invest in supporting policies and boost international influence through various cooperation programs, to achieve the goal of providing better design services for users globally,” said Xu Min, general manager of Homestyler.
For more information, please visit https://www.homestyler.com.
About Homestyler
Homestyler was jointly invested in by Easyhome New Retail Group and Alibaba Group. It is dedicated to provide 3D cloud design tools for designers worldwide and delivering a comprehensive suite of 3D+AI digital solutions to the furniture and home furnishing industry.

View original content:https://www.prnewswire.co.uk/news-releases/homestyler-to-recruit-first-batch-of-global-partners-in-20-countries-302127111.html

Continue Reading

Trending